Respiratory syncytial virus is a leading cause of bronchiolitis. In a prospective, multicenter, matched case–control study involving infants in France, nirsevimab decreased RSV-associated hospitalization by 83%.
The New England Journal of Medicine: Search Results in Pediatrics
